Spironolactone Use Not Linked to Increased Risk for Cancer
No significant associations seen for spironolactone with risk for breast, ovarian, bladder, kidney, gastric, esophageal cancers
Breast Cancer
Daily Aspirin Does Not Prevent Recurrence of Breast Cancer
Compared with placebo, daily aspirin did not improve invasive disease-free survival in patients with high-risk, HER2-negative breast cancer
Aromatase Inhibitors May Benefit Premenopausal Women With Breast Cancer
For premenopausal women receiving ovarian suppression, risk for breast cancer recurrence reduced with aromatase inhibitor versus tamoxifen
Neoadjuvant Pembrolizumab Plus Chemo Treats Early TNBC
Rate of event-free survival higher with neoadjuvant pembrolizumab plus chemo versus chemo alone for early triple-negative breast cancer
Biosimilars Could Cut Spending for Biologic Therapy in the US
Increased market growth of biosimilars that are similar to brand-name biologic agents has the potential to reduce spending on prescription drugs
Enobosarm Gets Fast Track Status for AR+ER+HER2- Metastatic Breast Cancer
Enobosarm is an oral, first-in-class, selective androgen receptor agonist.
BRCA2 Linked to Inferior Outcomes of Treatment With CDK4/6 Inhibitors Plus Endocrine Therapy
An analysis of germline-somatic interactions in breast cancer tumors revealed novel associations relevant to the disease’s progression and treatment resistance. For example, the study presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) showed that carriers of the BRCA2 mutation had inferior outcomes to treatment with first-line CDK4/6 inhibitors plus endocrine therapy. This could…
ctDNA Promising Biomarker in Ribociclib, Letrozole-Treated HR+/HER2- Advanced Breast Cancer
Liquid biopsies were used to determine whether ctDNA analysis was predictive of disease progression in women with HR+/HER2- breast cancer.
Samuraciclib Plus Fulvestrant Demonstrates Antitumor Activity in Advanced Breast Cancer
A single-arm cohort study sought to determine the efficacy of adding samuraciclib to treatment for ER-positive and/or PGR-positive, HER2-negative breast cancer.
Surgical Staging Affects Some QOL Scores in Early Breast Cancer
An analysis of patients in the INSEMA trial sought to determine the impact of no SLNB vs SLNB and SLNB alone vs SLNB with ALND on quality of life for patients with breast cancer.
